Intercept Pharma (ICPT) Misses Q4 EPS Views

Intercept Pharma (NASDAQ: ICPT) reported Q4 EPS of ($3.62), $0.47 worse than the analyst estimate of ($3.15). Revenue for the quarter came in at $447 thousand versus the consensus estimate of $720 thousand.

Planned 2016 Milestones

• PBC Program
  • Scheduled FDA Advisory Committee meeting April 7, 2016
  • PDUFA date May 29, 2016 with planned US launch in June if NDA is approved
  • Anticipated EU marketing authorization application decision in late 2016
• NASH Program
  • Continued enrollment of REGENERATE and CONTROL trials
  • Planning of NASH cirrhosis and non-invasive technology trials
• INT-767 Program
  • Completion of Phase 1 trial and planning of Phase 2 trial

For earnings history and earnings-related data on Intercept Pharma (ICPT) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Azitra, Inc. (AZTR) Tops Q2 EPS by 54c
• Omega Flex (OFLX) Tops Q2 EPS by 27c